Volver a ensayos clínicos
NCT00561470 Archived Fase 3

Aflibercept frente a placebo en combinación con irinotecán y 5-FU en el tratamiento de pacientes con cáncer colorrectal metastásico tras el fracaso de un régimen basado en oxaliplatino.

Guardar ClinicalTrials.gov

Descripción

El objetivo principal del estudio fue evaluar la eficacia de aflibercept (en comparación con el placebo) para aumentar la supervivencia global en participantes con cáncer colorrectal metastásico tratados con FOLFIRI (irinotecán, 5-fluorouracilo y leucovorina) y que previamente no habían respondido a un tratamiento con oxaliplatino para la enfermedad metastásica.

Los objetivos secundarios fueron comparar la supervivencia libre de progresión, evaluar la tasa de respuesta global, evaluar el perfil de seguridad, evaluar la inmunogenicidad de aflibercept intravenoso (IV) y evaluar la farmacocinética de aflibercept IV en ambos grupos de tratamiento.

Qué se prueba

Fármacos del ensayo

Biomarcadores que menciona

MET

Pueden ser requisito para entrar o para quedar fuera: los criterios de elegibilidad dicen cuál.

Evidencia de la diana molecular en cáncer colorrectal

Estos fármacos NO son el fármaco de este ensayo. Es la eficacia publicada de OTROS fármacos que atacan la misma diana molecular, mostrada como contexto — no se refiere a este ensayo concreto ni confirma elegibilidad. Revísalo siempre con tu oncólogo.

Aún no hay evidencia documentada en nuestra base para la diana o el fármaco de este ensayo. Esta sección crece a medida que se procesan nuevas publicaciones.

Criterios de elegibilidad

SexoTodos
Edad18 años o más
Voluntarios sanosNo

Se incluyeron en el estudio los participantes que cumplían los siguientes criterios de selección principales.

Criterios de inclusión:

  • Adenocarcinoma de colon o recto confirmado histológica o citológicamente.
  • Enfermedad metastásica que no es susceptible de un tratamiento potencialmente curativo.
  • Una y solo una línea de tratamiento previa para la enfermedad metastásica. Esta línea previa debe ser quimioterapia basada en oxaliplatino (los participantes que presentan una recaída dentro de los 6 meses posteriores a la finalización de la quimioterapia adyuvante basada en oxaliplatino son elegibles).
  • Se permite el tratamiento previo con bevacizumab.

Criterios de exclusión:

  • Terapia previa con irinotecán.
  • Estado funcional del Eastern Cooperative Oncology Group >2.

La información anterior no pretende incluir todas las consideraciones relevantes para la participación en un ensayo clínico.

Avísame de ensayos parecidos

Cuando se abra un ensayo nuevo en España para estos biomarcadores, te lo enviamos. Sin registro.

Información del ensayo

Número NCT
NCT00561470
Estado
Archived
Fase
Fase 3
Tipo de estudio
Intervencional (prueba un tratamiento)
Inscripción
1.226 participantes
Fecha de inicio
Nov 2007
Finalización prevista
Patrocinador
Sanofi

Ubicaciones221

España (6)
Sanofi-Aventis Investigational Site Number 724002
Barakaldo
Sanofi-Aventis Investigational Site Number 724001
Barcelona
Sanofi-Aventis Investigational Site Number 724005
Barcelona
Sanofi-Aventis Investigational Site Number 724003
Madrid
Sanofi-Aventis Investigational Site Number 724006
Madrid
Sanofi-Aventis Investigational Site Number 724007
Reus
Argentina (4)
Sanofi-Aventis Investigational Site Number 032003
Bahía Blanca
Sanofi-Aventis Investigational Site Number 032006
Buenos Aires
Sanofi-Aventis Investigational Site Number 032005
Ciudad de Buenos Aires
Sanofi-Aventis Investigational Site Number 032007
Salta
Australia (7)
Sanofi-Aventis Investigational Site Number 036004
Hornsby
Sanofi-Aventis Investigational Site Number 036001
Kingswood
Sanofi-Aventis Investigational Site Number 036002
Kurralta Park
Sanofi-Aventis Investigational Site Number 036003
Melbourne
Sanofi-Aventis Investigational Site Number 036005
Melbourne
Sanofi-Aventis Investigational Site Number 036007
Nedlands
Sanofi-Aventis Investigational Site Number 036006
Subiaco
Austria (1)
Sanofi-Aventis Investigational Site Number 040001
Vienna
Bélgica (7)
Sanofi-Aventis Investigational Site Number 056006
Bonheiden
Sanofi-Aventis Investigational Site Number 056002
Brussels
Sanofi-Aventis Investigational Site Number 056004
Brussels
Sanofi-Aventis Investigational Site Number 056007
Brussels
Sanofi-Aventis Investigational Site Number 056001
Ghent
Sanofi-Aventis Investigational Site Number 056005
Haine-Saint-Paul
Sanofi-Aventis Investigational Site Number 056003
Leuven
Brasil (8)
Sanofi-Aventis Investigational Site Number 076002
Porto Alegre
Sanofi-Aventis Investigational Site Number 076004
Porto Alegre
Sanofi-Aventis Investigational Site Number 076005
Porto Alegre
Sanofi-Aventis Investigational Site Number 076003
Rio de Janeiro
Sanofi-Aventis Investigational Site Number 076008
Rio de Janeiro
Sanofi-Aventis Investigational Site Number 076001
Santo André
Sanofi-Aventis Investigational Site Number 076006
São Paulo
Sanofi-Aventis Investigational Site Number 076007
São Paulo
Chile (5)
Sanofi-Aventis Investigational Site Number 152001
Santiago
Sanofi-Aventis Investigational Site Number 152002
Santiago
Sanofi-Aventis Investigational Site Number 152003
Santiago
Sanofi-Aventis Investigational Site Number 152005
Santiago
Sanofi-Aventis Investigational Site Number 152004
Viña del Mar
Chequia (3)
Sanofi-Aventis Investigational Site Number 203001
Brno
Sanofi-Aventis Investigational Site Number 203002
Brno
Sanofi-Aventis Investigational Site Number 203004
Prague
Dinamarca (2)
Sanofi-Aventis Investigational Site Number 208003
Aalborg
Sanofi-Aventis Investigational Site Number 208001
Odense C
Estonia (2)
Sanofi-Aventis Investigational Site Number 233002
Tallinn
Sanofi-Aventis Investigational Site Number 233001
Tartu
Francia (5)
Sanofi-Aventis Investigational Site Number 250002
Brest
Sanofi-Aventis Investigational Site Number 250004
Clichy Cx
Sanofi-Aventis Investigational Site Number 250005
La Roche-sur-Yon
Sanofi-Aventis Investigational Site Number 250001
Lyon
Sanofi-Aventis Investigational Site Number 250003
Paris
Alemania (6)
Sanofi-Aventis Investigational Site Number 276003
Aschaffenburg
Sanofi-Aventis Investigational Site Number 276002
Essen
Sanofi-Aventis Investigational Site Number 276001
Halle
Sanofi-Aventis Investigational Site Number 276004
Magdeburg
Sanofi-Aventis Investigational Site Number 276005
Magdeburg
Sanofi-Aventis Investigational Site Number 276006
München
Grecia (5)
Sanofi-Aventis Investigational Site Number 300004
Athens
Sanofi-Aventis Investigational Site Number 300005
Athens
Sanofi-Aventis Investigational Site Number 300001
Heraklion
Sanofi-Aventis Investigational Site Number 300002
Ilion, Athens
Sanofi-Aventis Investigational Site Number 300003
Pátrai
Italia (8)
Sanofi-Aventis Investigational Site Number 380007
Ancona
Sanofi-Aventis Investigational Site Number 380005
Aviano
Sanofi-Aventis Investigational Site Number 380004
Candiolo
Sanofi-Aventis Investigational Site Number 380003
Genova
Sanofi-Aventis Investigational Site Number 380001
Milan
Sanofi-Aventis Investigational Site Number 380002
Milan
Sanofi-Aventis Investigational Site Number 380008
Rozzano
Sanofi-Aventis Investigational Site Number 380006
San Giovanni Rotondo
Países Bajos (5)
Sanofi-Aventis Investigational Site Number 528004
Amsterdam
Sanofi-Aventis Investigational Site Number 528001
Blaricum
Sanofi-Aventis Investigational Site Number 528005
Breda
Sanofi-Aventis Investigational Site Number 528002
Rotterdam
Sanofi-Aventis Investigational Site Number 528003
Sittard-Geleen
Nueva Zelanda (2)
Sanofi-Aventis Investigational Site Number 554009
Auckland
Sanofi-Aventis Investigational Site Number 554010
Christchurch
Noruega (3)
Sanofi-Aventis Investigational Site Number 578002
Bergen
Sanofi-Aventis Investigational Site Number 578001
Oslo
Sanofi-Aventis Investigational Site Number 578003
Stavanger
Polonia (7)
Sanofi-Aventis Investigational Site Number 616005
Częstochowa
Sanofi-Aventis Investigational Site Number 616004
Elblag
Sanofi-Aventis Investigational Site Number 616007
Krakow
Sanofi-Aventis Investigational Site Number 616003
Lodz
Sanofi-Aventis Investigational Site Number 616002
Poznan
Sanofi-Aventis Investigational Site Number 616006
Rybnik
Sanofi-Aventis Investigational Site Number 616001
Wroclaw
Puerto Rico (1)
Sanofi-Aventis Investigational Site Number 630001
San Juan
Rumanía (7)
Sanofi-Aventis Investigational Site Number 642004
Alba Iulia
Sanofi-Aventis Investigational Site Number 642001
Bucharest
Sanofi-Aventis Investigational Site Number 642002
Bucharest
Sanofi-Aventis Investigational Site Number 642007
Bucharest
Sanofi-Aventis Investigational Site Number 642003
Cluj-Napoca
Sanofi-Aventis Investigational Site Number 642006
Iași
Sanofi-Aventis Investigational Site Number 642005
Suceava
Rusia (6)
Sanofi-Aventis Investigational Site Number 643001
Moscow
Sanofi-Aventis Investigational Site Number 643002
Moscow
Sanofi-Aventis Investigational Site Number 643006
Moscow
Sanofi-Aventis Investigational Site Number 643003
Saint Petersburg
Sanofi-Aventis Investigational Site Number 643004
Saint Petersburg
Sanofi-Aventis Investigational Site Number 643007
Saint Petersburg
Sudáfrica (7)
Sanofi-Aventis Investigational Site Number 710004
Cape Town
Sanofi-Aventis Investigational Site Number 710005
Durban
Sanofi-Aventis Investigational Site Number 710008
Durban
Sanofi-Aventis Investigational Site Number 710001
Parktown
Sanofi-Aventis Investigational Site Number 710006
Port Elizabeth
Sanofi-Aventis Investigational Site Number 710003
Pretoria
Sanofi-Aventis Investigational Site Number 710007
Pretoria
Corea del Sur (5)
Sanofi-Aventis Investigational Site Number 410001
Goyang
Sanofi-Aventis Investigational Site Number 410002
Seoul
Sanofi-Aventis Investigational Site Number 410003
Seoul
Sanofi-Aventis Investigational Site Number 410004
Seoul
Sanofi-Aventis Investigational Site Number 410005
Seoul
Suecia (3)
Sanofi-Aventis Investigational Site Number 752002
Stockholm
Sanofi-Aventis Investigational Site Number 752003
Sundsvall
Sanofi-Aventis Investigational Site Number 752001
Uppsala
Turquía (5)
Sanofi-Aventis Investigational Site Number 792005
Adana
Sanofi-Aventis Investigational Site Number 792001
Ankara
Sanofi-Aventis Investigational Site Number 792004
Ankara
Sanofi-Aventis Investigational Site Number 792002
Izmir
Sanofi-Aventis Investigational Site Number 792003
Kayseri
Ucrania (4)
Sanofi-Aventis Investigational Site Number 804005
Dnipropetrovsk
Sanofi-Aventis Investigational Site Number 804004
Donetsk
Sanofi-Aventis Investigational Site Number 804002
Kharkiv
Sanofi-Aventis Investigational Site Number 804006
Kharkiv
Reino Unido (10)
Sanofi-Aventis Investigational Site Number 826001
Aberdeen
Sanofi-Aventis Investigational Site Number 826010
Bournemouth
Sanofi-Aventis Investigational Site Number 826009
Dudley
Sanofi-Aventis Investigational Site Number 826004
London
Sanofi-Aventis Investigational Site Number 826007
London
Sanofi-Aventis Investigational Site Number 826008
London
Sanofi-Aventis Investigational Site Number 826011
London
Sanofi-Aventis Investigational Site Number 826002
Manchester
Sanofi-Aventis Investigational Site Number 826003
Northwood
Sanofi-Aventis Investigational Site Number 826005
Sutton
Estados Unidos (87)
Sanofi-Aventis Investigational Site Number 840119
Birmingham, Alabama
Sanofi-Aventis Investigational Site Number 840074
Muscle Shoals, Alabama
Sanofi-Aventis Investigational Site Number 840093
Hot Springs, Arizona
Sanofi-Aventis Investigational Site Number 840080
Anaheim, California
Sanofi-Aventis Investigational Site Number 840076
Fountain Valley, California
Sanofi-Aventis Investigational Site Number 840120
Fountain Valley, California
Sanofi-Aventis Investigational Site Number 840073
Greenbrae, California
Sanofi-Aventis Investigational Site Number 840101
Hayward, California
Sanofi-Aventis Investigational Site Number 840046
La Jolla, California
Sanofi-Aventis Investigational Site Number 840116
Loma Linda, California
Sanofi-Aventis Investigational Site Number 840048
Long Beach, California
Sanofi-Aventis Investigational Site Number 840201
Oakland, California
Sanofi-Aventis Investigational Site Number 840901
Roseville, California
Sanofi-Aventis Investigational Site Number 840042
Sacramento, California
Sanofi-Aventis Investigational Site Number 840301
Sacramento, California
Sanofi-Aventis Investigational Site Number 840112
Salinas, California
Sanofi-Aventis Investigational Site Number 840006
San Diego, California
Sanofi-Aventis Investigational Site Number 840106
San Diego, California
Sanofi-Aventis Investigational Site Number 840206
San Diego, California
Sanofi-Aventis Investigational Site Number 840306
San Diego, California
Sanofi-Aventis Investigational Site Number 840406
San Diego, California
Sanofi-Aventis Investigational Site Number 840506
San Diego, California
Sanofi-Aventis Investigational Site Number 840606
San Diego, California
Sanofi-Aventis Investigational Site Number 840706
San Diego, California
Sanofi-Aventis Investigational Site Number 840806
San Diego, California
Sanofi-Aventis Investigational Site Number 840906
San Diego, California
Sanofi-Aventis Investigational Site Number 840401
San Francisco, California
Sanofi-Aventis Investigational Site Number 840601
San Jose, California
Sanofi-Aventis Investigational Site Number 840501
Santa Clara, California
Sanofi-Aventis Investigational Site Number 840801
South San Francisco, California
Sanofi-Aventis Investigational Site Number 840001
Vallejo, California
Sanofi-Aventis Investigational Site Number 840701
Walnut Creek, California
Sanofi-Aventis Investigational Site Number 840071
Stamford, Connecticut
Sanofi-Aventis Investigational Site Number 840014
Newark, Delaware
Sanofi-Aventis Investigational Site Number 840089
Boynton Beach, Florida
Sanofi-Aventis Investigational Site Number 840031
Gainesville, Florida
Sanofi-Aventis Investigational Site Number 840041
Gainesville, Florida
Sanofi-Aventis Investigational Site Number 840122
Miami, Florida
Sanofi-Aventis Investigational Site Number 840079
The Villages, Florida
Sanofi-Aventis Investigational Site Number 840087
Chicago, Illinois
Sanofi-Aventis Investigational Site Number 840019
Decatur, Illinois
Sanofi-Aventis Investigational Site Number 840115
Elk Grove Village, Illinois
Sanofi-Aventis Investigational Site Number 840010
Naperville, Illinois
Sanofi-Aventis Investigational Site Number 840113
Quincy, Illinois
Sanofi-Aventis Investigational Site Number 840047
Indianapolis, Indiana
Sanofi-Aventis Investigational Site Number 840072
Indianapolis, Indiana
Sanofi-Aventis Investigational Site Number 840034
Munster, Indiana
Sanofi-Aventis Investigational Site Number 840088
Louisville, Kentucky
Sanofi-Aventis Investigational Site Number 840096
Paducah, Kentucky
Sanofi-Aventis Investigational Site Number 840043
Baton Rouge, Louisiana
Sanofi-Aventis Investigational Site Number 840084
Metairie, Louisiana
Sanofi-Aventis Investigational Site Number 840015
New Orleans, Louisiana
Sanofi-Aventis Investigational Site Number 840070
Rockville, Maryland
Sanofi-Aventis Investigational Site Number 840029
Salisbury, Maryland
Sanofi-Aventis Investigational Site Number 840053
Pontiac, Michigan
Sanofi-Aventis Investigational Site Number 840021
Saint Louis Park, Minnesota
Sanofi-Aventis Investigational Site Number 840081
Kansas City, Missouri
Sanofi-Aventis Investigational Site Number 840052
St Louis, Missouri
Sanofi-Aventis Investigational Site Number 840114
St Louis, Missouri
Sanofi-Aventis Investigational Site Number 840049
Las Vegas, Nevada
Sanofi-Aventis Investigational Site Number 840044
Albuquerque, New Mexico
Sanofi-Aventis Investigational Site Number 840036
Albany, New York
Sanofi-Aventis Investigational Site Number 840094
Lake Success, New York
Sanofi-Aventis Investigational Site Number 840017
Syracuse, New York
Sanofi-Aventis Investigational Site Number 840097
Syracuse, New York
Sanofi-Aventis Investigational Site Number 840035
Burlington, North Carolina
Sanofi-Aventis Investigational Site Number 840024
Charlotte, North Carolina
Sanofi-Aventis Investigational Site Number 840026
Charlotte, North Carolina
Sanofi-Aventis Investigational Site Number 840005
Goldsboro, North Carolina
Sanofi-Aventis Investigational Site Number 840004
Hendersonville, North Carolina
Sanofi-Aventis Investigational Site Number 840075
Winston-Salem, North Carolina
Sanofi-Aventis Investigational Site Number 840098
Cincinnati, Ohio
Sanofi-Aventis Investigational Site Number 840011
Kettering, Ohio
Sanofi-Aventis Investigational Site Number 840086
Middletown, Ohio
Sanofi-Aventis Investigational Site Number 840008
Toledo, Ohio
Sanofi-Aventis Investigational Site Number 840039
Portland, Oregon
Sanofi-Aventis Investigational Site Number 840118
Bethlehem, Pennsylvania
Sanofi-Aventis Investigational Site Number 840033
Philadelphia, Pennsylvania
Sanofi-Aventis Investigational Site Number 840012
Pittsburgh, Pennsylvania
Sanofi-Aventis Investigational Site Number 840082
Pawtucket, Rhode Island
Sanofi-Aventis Investigational Site Number 840095
Woonsocket, Rhode Island
Sanofi-Aventis Investigational Site Number 840085
Charleston, South Carolina
Sanofi-Aventis Investigational Site Number 840037
Spartanburg, South Carolina
Sanofi-Aventis Investigational Site Number 840078
Corpus Christi, Texas
Sanofi-Aventis Investigational Site Number 840117
Temple, Texas
Sanofi-Aventis Investigational Site Number 840099
Seattle, Washington
Sanofi-Aventis Investigational Site Number 840002
Marshfield, Wisconsin

Los hospitales y su estado vienen de ClinicalTrials.gov. Antes de desplazarte, confirma con el hospital que siguen incluyendo pacientes.

Esta ficha resume el registro oficial del ensayo. Si te interesa, coméntalo con tu oncólogo: es quien puede valorar si encajas y derivarte.